Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision Next revisionBoth sides next revision | ||
| content:fires [2020/02/14 17:35] – [Pathophysiology] icna | content:fires [2020/02/14 17:47] – [Treatment] icna | ||
|---|---|---|---|
| Line 47: | Line 47: | ||
| * The efficacy of ketogenic diet as an alternative to pharmacotherapy in FIRES has been reported with favourable outcomes[(: | * The efficacy of ketogenic diet as an alternative to pharmacotherapy in FIRES has been reported with favourable outcomes[(: | ||
| * Deep brain stimulation of the centromedian thalamic nuclei (CMN-DBS) has been reported in some cases with where generalised seizures have been abolished but did not have a lasting effect on focal seizures burden[(: | * Deep brain stimulation of the centromedian thalamic nuclei (CMN-DBS) has been reported in some cases with where generalised seizures have been abolished but did not have a lasting effect on focal seizures burden[(: | ||
| - | * There are also case reports on the use of Anakinra (a recombinant version of the human interleukin-1 receptor antagonist) in FIRES but with variable outcomes[(: | + | * There are also case reports on the use of [[Anakinra]] (a recombinant version of the human interleukin-1 receptor antagonist) in FIRES but with variable outcomes[(: |
| - | * Gofshteyn et al.(2017) reported an open label case series cannabadiol (Epidiolex, GW Pharma) was used on emergency or expanded investigational protocols in either the acute or chronic phase of illness and showed improvement in seizure frequency and duration[(: | + | * Gofshteyn et al.(2017) reported an open label case series |
| ==== References ==== | ==== References ==== | ||
| <columns 100% 50%> | <columns 100% 50%> | ||